Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Carcinoma, Non-Small-Cell Lung 50Prostatic Neoplasms 23Lung Neoplasms 17Breast Neoplasms 16Squamous Cell Carcinoma of Head and Neck 13Neoplasms 9Stomach Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Transitional Cell 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Non-Muscle Invasive Bladder Neoplasms 5Endometrial Neoplasms 5Carcinoma, Squamous Cell 5Prostatic Neoplasms, Castration-Resistant 4Oropharyngeal Neoplasms 4Small Cell Lung Carcinoma 3Salivary Gland Neoplasms 3Ovarian Neoplasms 3Nasopharyngeal Carcinoma 3HER2-positive Breast Cancer 3Esophageal Squamous Cell Carcinoma 3Carcinoma 3Anatomic Stage I Breast Cancer AJCC v8 3Adenocarcinoma 3Vaccinia 2Solid Tumors 2Sarcoma 2

Interventions

Doxorubicin 13Specimen Handling 12pembrolizumab 11Magnetic Resonance Spectroscopy 10Biopsy 10Cyclophosphamide 9X-Rays 7Ifosfamide 7Radiotherapy 6Phantoms, Imaging 6Gemcitabine 6liposomal doxorubicin 5Nivolumab 5tazemetostat 4palbociclib 4fludarabine 4atezolizumab 4Temozolomide 4Radiation 4Nuclear Medicine Department, Hospital 4Irinotecan 4larotrectinib 3cabozantinib 3Surveys and Questionnaires 3Ipilimumab 3Carboplatin 3Bevacizumab 3ulixertinib 2tipifarnib 2selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma × Docetaxel × 90 days × Clear all
NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT04577014 2026-04-14

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
98 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡